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Summary New T cell-based blood tests for tuberculosis infection could improve diagnosis of
tuberculosis but their clinical utility remains unknown. We describe the role of the ELISpot test
in the diagnostic work-up of 13 patients presenting with suspected tuberculosis in routine prac-
tice. Of the seven patients with a final diagnosis of active tuberculosis, all were positive by
ELISpot including three with false-negative tuberculin skin test results. Rapid determination
of tuberculosis infection by ELISpot accelerated the diagnosis of tuberculosis, enabling early
treatment initiation.
ª 2006 The British Infection Society. Published by Elsevier Ltd. Open access under CC BY license. * Corresponding author. Tuberculosis Immunology Group, Nuffield
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Successful tuberculosis (TB) control depends on rapid
detection and treatment of active cases, yet diagnosis is
often difficult and delayed. Although sputum smear-positive
pulmonary TB is readily diagnosed within hours, diagnosis of
extra-pulmonary and smear-negative pulmonary TB can takevier Ltd. Open access under CC BY license. 
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Figure 1 Demonstration of how periods of delay arise before treatment of active TB is initiated.much longer and bacteriological confirmation is often not
possible.1,2
Causes for delay in initiation of TB treatment are
multiple, and can be visualised along a timeline (Fig. 1).
Studies examining health care system delays have shown
that the longest delay is in deciding to initiate treat-
ment.3,4 Treatment delay is common and prolonged be-
cause physicians have to make a presumptive diagnosis
whilst still awaiting definitive culture results, knowing
that these will frequently be falsely negative.
The tuberculin skin test (TST), which provides evidence
of M. tuberculosis infection, is widely used to support
clinical and radiological findings in the evaluation of pa-
tients with suspected tuberculosis.5 A positive TST result
can help in the decision to start treatment while bacteri-
ological confirmation is awaited or lacking. However, the
greatest utility of a test of M. tuberculosis infection lies
in its potential to exclude a diagnosis of TB when other
tests are negative. This requires a test with high diagnos-
tic sensitivity to minimise the possibility of falsely ruling
out tuberculosis.
The poor sensitivity of TST in young children and
immunosuppressed people makes it impossible to interpret
negative TST results in these groups. Moreover, up to 25% of
immunocompetent adults with active tuberculosis may
have a negative or ambiguous result.6
A recently developed rapid blood test for M. tuberculosis
infection, the enzyme-linked immunospot assay (ELISpot),
may offer a more accurate alternative to the TST. The assay
detects Tcells specific for antigens inM. tuberculosis, which
are absent from BCG and most environmental bacteria.7 It is
therefore not confounded by prior BCG vaccination and is
more specific than TST.7e9 ELISpot was found to have a
sensitivity of 96% in HIV-negative adults with culture-
confirmed active TB,7 and 92% in HIV-positive patients with
pulmonary TB.10 These attributes suggest that ELISpot could
improve and accelerate the diagnostic evaluation of patients
with suspected TB.
The regulatory-approved, commercially available ELISpot
assay, T-SPOT.TB (Oxford Immunotec Ltd, Abingdon, UK) is
based on the assay used here, developed by Lalvani.7e10T-SPOT.TB and an alternative interferon-gamma release
assay, the whole blood ELISA (QuantiFERON-Gold, Cellestis,
Carnegie, Australia), have recently been approved by the
National Institute for Clinical Excellence (NICE) for diagnosis
of latent TB infection and as adjunctive tests for the evalua-
tion of patients with active TB. However, clinical data on the
performance of these tests in TB patients and how they will
impact on clinical decision-making is limited. The most rele-
vant target population is that in which the test will actually
be used in practice: patients presenting with suspected TB
whose diagnoses are unknown at the time of testing.11,12
We therefore monitored the diagnostic performance of
ELISpot in patients with suspected TB in routine clinical
practice.
We received requests to perform ELISpot assays from
physicians at two institutions who were aware of the
published literature on ELISpot. The decision to request
an ELISpot blood test was made by the referring physicians
and arose from their routine clinical practice. To date, 13
patients with suspected active TB have been tested and we
report the comparative performance of ELISpot and TST
and discuss how the availability of ELISpot results enabled
early initiation of treatment.
Methods
Study population
Six child and seven adult inpatients from the Departments
of Pulmonary Medicine and Paediatrics, Modena University
Hospital, Italy, and the Department of General Internal
Medicine, Battle Hospital, Reading, UK, being investigated
for suspected tuberculosis, were referred for ELISpot
testing. None had symptoms or signs of HIV infection or
were suspected of HIV carriage, and all were from pop-
ulations at low risk of HIV. Of the 13, seven had a final
diagnosis of active tuberculosis (Tables 1 and 2). All pa-
tients, or their parents, gave verbal informed consent to
have an ELISpot blood test. Ethical approval was granted
by Central Oxford Research Ethics Committee, Modena
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171able 1 Clinical characteristics and test results of the seven active tuberculosis cases
Case 1 Case 2 Case 3 Case 4 Case 5
ge (years) 65 54 71 27 2
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linical
features
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BCG vaccinated Unvaccinated BCG vaccinated Unvaccinated Unvaccinate
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LISpot Resultsd Positive Positive Positive Positive Positive
a High resolution computerised tomography.
b Ziel Nielson.
c Bronchioalveolar lavage.
d Duplicate pairs of wells were scored positive if they contained a mean of at least five spot-forming cells more than the mean of th
was at least twice the mean of the negative control wells.
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ology
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positive for H. influenzae
Gastric aspirate
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M. tuberculosis
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and culture)
Sputum and BAL
negative for
M. tuberculosis
Gastric aspirate neg
for M. tuberculosis
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culture)
for final
lusion of TB
Clinical response to antibiotic
therapy for community-acquired
pneumonia. Final diagnosis:
bacterial pneumonia
Negative microbiology,
no symptoms. Final
diagnosis: previously
treated TB leading to
bronchiectasis
Clinical response
to first-line antibiotics
for community-acquired
chest infection. Final
diagnosis: LTBIb
Symptoms self-limit
Final diagnosis: LTB
ux result Negative (0 mm) Negative (3 mm) Positive (20 mm) Positive (45 mm)
ot resultsa Negative Negative Positive Positive
plicate pairs of wells were scored positive if they contained a mean of at least five spot-forming cells more than the mean o
t least twice the mean of the negative control wells.
BI, latent TB infection. All patients diagnosed with LTBI remained well during 18 months follow-up without treatment for
T cell blood test for TB in clinical practice e173University Hospital Ethics Committee and the Battle Hospi-
tal Ethics Committee.
Procedures
ELISpot was performed as previously described using 35
overlapping peptides spanning the length of ESAT-6 and
CFP10 arranged in six pools and 250,000 peripheral blood
mononuclear cells were added to each ELISpot well.9 All
assays produced evaluable results. The assays were car-
ried out within 1 week of initial presentation to the hos-
pital. Both ELISpot and TSTs were performed during the
diagnostic evaluation period before therapy was com-
menced. Twelve of the thirteen TSTs were performed
using the Mantoux method in accordance with guide-
lines. Five international units of purified protein deriva-
tive (PPD) were injected intradermally and the tests
were interpreted within 72 h. A positive result was de-
fined as greater than 5 mm regardless of BCG status.
Case 4 had a Heaf test performed via the standard
method using a six-needle disposable Heaf gun injecting
100,000 units per ml of PPD, and was read 1 week after-
wards.9 All tests were interpreted by an experienced
physician.
Results and discussion
Of the 13 patients, seven had a final diagnosis of active
TB. Of these, two were culture-confirmed, one was
confirmed by nucleic acid amplification and the remaining
four were diagnosed on clinical and radiological grounds.
All had an excellent response to anti-TB therapy (Table 1).
Active TB was clinically and microbiologically excluded in
the remaining six patients (Table 2). Of these, two were
negative by TST and ELISpot (one with pneumonia, the
other with bronchiectasis, cases 8 and 9); three were pos-
itive by TST and ELISpot and were treated for latent TB
infection and one, a 7-month-old infant with recent TB ex-
posure and respiratory symptoms, had a positive ELISpot
but negative TST, and was treated for latent TB infection
(case 13). All six have remained well over 18 months fol-
low-up.
All seven active TB cases were ELISpot positive but
three were TST negative at presentation. Of these three,
case 1 presented with pyrexia and night sweats and had
inconclusive radiological findings. Although TB was in the
differential diagnosis, there was no definitive evidence,
and acid fast stains and the skin test were negative. The
positive ELISpot result, performed 3 days after the nega-
tive skin test, provided the only specific evidence for TB
infection, making a diagnosis of TB much more likely and
prompting early initiation of therapy which resulted in an
excellent clinical response. Initiation of anti-TB treat-
ment would otherwise likely have been delayed several
weeks. Case 2 presented with constrictive pericarditis
and pulmonary nodules. Although the clinical picture
was compatible with TB, acid fast stains, culture of bron-
choalveolar lavage fluid and pericardial biopsy tissue
were negative, as was the skin test. A positive ELISpot
result provided definitive evidence of TB infection,
prompting the presumptive diagnosis of tuberculouspericarditis and initiation of anti-tuberculous chemother-
apy just 4 days after admission. Case 7 was a heavy
smoker presenting with cough and haemoptysis and two
nodules in the right upper lung, a picture highly suggestive
of lung cancer. However the positive ELISpot resultd
despite the negative TST resultdsuggested a diagnosis of
pulmonary TB, then confirmed by surgical biopsy which
revealed caseating granulomas and was positive on nucleic
acid amplification.
Anergy is defined as the absence of the cutaneous
delayed type hypersensitivity (DTH) response to PPD during
active tuberculosis. These cases suggest that the ELISpot is
less susceptible to this anergy, giving fewer false-negative
results. None of the three cases with active TB and
a negative skin test had intrinsic or iatrogenic immunosup-
pression to account for the negative skin test results.
Therefore, these false-negative results were likely caused
by the active tuberculosis per se. The ability of ELISpot to
detect TB infection in the setting of anergic skin test
results is likely due to the fact that a greater number of
M. tuberculosis antigen specific Th1-type T cells are
required to produce a cutaneous DTH response than an
ELISpot response.13
Our report has several limitations. Only two of seven TB
patients had a gold-standard culture-confirmed microbio-
logical diagnosis. However, the clinical and radiological
picture in the remaining cases was either compatible with
or strongly suggestive of active TB and was further
corroborated by the excellent response to anti-TB therapy
in each case. Performance of ELISpot in patients with
a clinical diagnosis of TB is highly relevant for clinical
practice, where culture-confirmation is not possible in
a significant proportion of patients.
Of the 13 patients with suspected TB, 11 had positive
ELISpot results of whom seven were treated for active
disease (Table 1). In the remaining four ELISpot-positive
patients, active TB was clinically and microbiologically
excluded and they were treated for latent TB infection;
three of these patients also had positive TST results
(Table 2). Thus, as expected for a test of infection, ELISpot
did not help in differentiating active TB disease from latent
TB infection, which remains a distinction based on clinical
judgement.
The numbers are small but likely to be representative of
patients presenting to hospital with suspected active TB in
general, as they were referred from routine clinical
practice. However, it is difficult to rule out possible
selection bias employed by the requesting physicians. As
collaborating physicians who were aware of the ELISpot
test, they are also potentially not representative of the
majority of doctors.
In summary, we have presented three cases of active
tuberculosis with a negative tuberculin skin test and
a positive ELISpot. In each of these cases the ELISpot
assay enabled a diagnosis to be reached more rapidly than
would have otherwise been possible, allowing rapid treat-
ment initiation. The ELISpot has shown greater sensitivity
as a diagnostic test compared to the TST in latent TB9 and
active TB.7 Our preliminary findings suggest that this
increased sensitivity can result in improved diagnostic
evaluation of TB suspects with false-negative TST results
in routine clinical practice.
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